Build storage around the instructions for the specific product, not a universal internet rule. Document receipt, location, conditions and handling events so the material’s history stays understandable to the whole research team.
Why product-specific instructions lead
Lyophilized means freeze-dried; it does not guarantee stability. Sequence and formulation can affect stability, while moisture, air and light may matter. Technical guidance also notes that solutions are generally less stable than lyophilized material and that repeated freeze-thaw cycles can be detrimental. None of those general considerations replaces the supplied instructions. GenScript peptide storage and handling
Create a simple storage record
| Item | Detail |
|---|---|
| At receipt | Date, label condition, product and lot identifiers |
| Location | Named unit, shelf or controlled area |
| Instructions | The exact product-specific temperature and light guidance |
| Events | Moves, excursions and handling dates |
Avoid silent assumptions
Do not calculate a concentration from vial milligrams alone, and do not improvise preparation or administration from storage text. If instructions are missing, contradictory or detached from the identified lot, pause and request the applicable document.
Plan for traceability
Use a location name another team member can understand, and retain the version of the instruction sheet used for the decision. If material moves between storage units, record when and why. A compact log is more useful than reconstructing events from memory after a deviation.
After a temperature excursion: what the record can tell you
A delivery arrives warm. A refrigerator alarm goes off overnight. The immediate question is whether the material has changed. A temperature record helps reconstruct what happened, but it cannot answer that question on its own.
Keep two records separate: the exposure history and the evidence used to interpret it. This distinction makes a storage decision easier to explain, check and revisit.
An exposure record is not a stability result
A logger records temperature at its sensor. Its location, sampling interval and coverage determine what you can say about the shipment or storage unit. A measurement taken at receipt describes that moment; it does not reconstruct the entire journey.
Stability evidence asks a different question: how did defined properties of a particular material change over time under specified conditions? The compound, formulation, physical form and container belong to that answer. A study of a solution cannot simply supply a shelf life for a freeze-dried powder.
What two peptide studies show
Hawe and colleagues examined oxytocin solutions under accelerated laboratory conditions in 2009. They varied pH and temperature, measured loss of intact oxytocin by chromatography, and used additional methods to identify degradation products. The changes depended on the conditions tested. Hawe et al., 2009
This was an analytical experiment, not a clinical trial. It explains why a stability statement needs its formulation and conditions attached. It does not establish how long a different peptide, a lyophilized material or a PLP batch can remain outside its specified conditions.
In 2019, Nguyen and colleagues compared oxytocin ampoules from four manufacturers using accelerated storage and repeated warm/refrigerated cycles. They measured oxytocin content with a validated HPLC-UV method. Products carrying different storage labels generally showed similar degradation profiles under the tested accelerated conditions, with one exception at the highest temperature. Nguyen et al., 2019
The practical reading lesson is narrow: a storage label alone is not a comparative stability experiment. The study examined selected liquid products under controlled protocols, not Canadian parcel deliveries or the materials in this catalogue. Neither paper supplies a universal temperature allowance.
The Canadian documentation principle
Health Canada’s GUI-0069 guidance says drug-storage excursions should be investigated and decisions about affected stock supported by evidence, such as stability data and technical justification. Its scope is drug storage and transportation. It is useful context for understanding an evidence-based assessment, not proof that a research supplier or product meets drug requirements. Health Canada GUI-0069
Build a record someone else can check
For laboratory documentation, the following worksheet separates observations from conclusions. It is an editorial aid, not a validated testing protocol or a release specification. Follow the laboratory’s own procedures and the instructions applicable to the identified material.
| Record | What to capture |
|---|---|
| Material | Exact name, lot, physical form and container. Keep the instruction sheet and its version with the record. |
| Observed exposure | Original logger file, sensor location, interval and time zone. Record the measured range and duration outside the applicable conditions where known. |
| Gaps and uncertainty | State when recording began and ended. Mark missing coverage, uncertain placement or an estimated duration explicitly. |
| Handling history | Receipt, transfer and alarm times; packaging observations; any earlier recorded excursions. Do not overwrite the original trace. |
| Supporting evidence | Request the applicable stability document or written assessment. Note whether it covers the same formulation, form, packaging and exposure pattern. |
| Decision record | Who reviewed it, when, what evidence was used, the decision and any unresolved questions. Keep the response with the lot record. |
A worked example: known exposure, unknown outcome
Imagine a hypothetical logger that records three hours outside a material’s stated range. No applicable excursion assessment is available. The defensible note is: “Recorded excursion; effect on material not established; assessment requested.” It is not “definitely ruined”, and it is not “still fine”. This example describes no actual shipment or PLP product.
A useful request to the supplier identifies the lot and attaches the original trace, then asks which evidence supports their assessment. If the response relies on another formulation or physical form, record that mismatch rather than silently treating it as equivalent. While the issue remains unresolved, keep the material clearly identified and follow the laboratory’s hold and review procedure.
Keep authorization separate
A complete storage history, stability report or COA does not establish Canadian marketing authorization. Health Canada’s Drug Product Database is a separate resource for checking drugs authorized for sale. Neither a familiar ingredient name nor a well-documented shipment answers the status of a different product. Health Canada Drug Product Database
Use the batch-record guide to connect the lot and documents, and the Canadian product-information guide for the separate authorization question.
Practical checklist
- Assign responsibility for receiving and logging.
- Minimize unnecessary handling.
- Preserve the original label and instructions.
- Record deviations rather than reconstructing them later.
References
Each reference describes a particular study or document. It does not verify any Proof Line Peptides lot, and it does not indicate that a product is authorized for sale in Canada.
- GenScript technical resource on peptide storage and handling considerations. View source
- Hawe A, Poole R, Romeijn S, Kasper P, van der Heijden R, Jiskoot W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharmaceutical Research. 2009;26:1679-1688 (online 3 April 2009). doi:10.1007/s11095-009-9878-2. Original laboratory degradation study: oxytocin solutions at four pH values and 40-80°C, characterized by chromatography and mass spectrometry. Limits: one peptide, selected formulations and accelerated conditions; no human outcomes, lyophilized-product validation or PLP testing. Checked 29 October 2026. DOI · PubMed
- Nguyen TH et al. Temperature stability of oxytocin ampoules labelled for storage at 2°C-8°C and below 25°C: an observational assessment under controlled accelerated and temperature cycling conditions. BMJ Open. 2019-07-26;9:e029083. doi:10.1136/bmjopen-2019-029083. Original controlled laboratory stability assessment: ampoules from four manufacturers at 30, 40 and 50°C, accelerated testing up to 120 days and cycling up to 135 days. Limits: selected ampoules and controlled exposures; not a clinical trial or a real-world Canadian shipping study. Checked via PubMed 29 October 2026. DOI · PubMed
- Health Canada. Guidelines for environmental control of drugs during storage and transportation (GUI-0069). Issued/implemented 24 August 2020. Official guidance, not experimental research; relevant sections 4.1, 5.1 and 5.4. Limit: drug-sector scope; citing it does not establish compliance, a universal excursion limit or any supplier's product quality. Checked 29 October 2026. View source
- Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source
The two oxytocin papers are explanatory examples of how stability evidence is reported, not findings about any PLP material. Health Canada sources describe drug-sector expectations and the Drug Product Database; they do not verify any PLP batch or authorize any product.
AI-assisted research and drafting; references checked 29 October 2026. Laboratory documentation only. No dosing, preparation, administration or product-specific storage allowance is provided.